Article
Mutations in CHEK2 associated with prostate cancer risk.
American journal of human genetics - 1 Feb 2003
Dong Xiangyang, Wang Liang, Taniguchi Ken, Wang Xianshu, Cunningham Julie M, McDonnell Shannon K, Qian Chiping, Marks Angela F, Slager Susan L, Peterson Brett J, Smith David I, Cheville John C, Blute Michael L, Jacobsen Steve J, Schaid Daniel J, Tindall Donald J, Thibodeau Stephen N, Liu Wanguo
Abstract excerpt
The DNA-damage-signaling pathway has been implicated in all human cancers. However, the genetic defects and the mechanisms of this pathway in prostate carcinogenesis remain poorly understood. In this study, we analyzed CHEK2, the upstream regulator of p53 in the DNA-damage-signaling pathway, in several groups of patients with prostate cancer. A total of 28 (4.8%) germline CHEK2 mutations (16 of which were unique)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.